Video
:quality(75)/cdn.jwplayer.com/v2/media/k3QH6hUo/poster.jpg)
Duración: 03:49
Nuevo fármaco del laboratorio AstraZeneca ayuda a reducir riesgo de enfermedad grave
La empresa farmacéutica británica informó que el fármaco experimental contra la Covid-19 de AstraZeneca contribuyó a reducir el riesgo de enfermedad grave o muerte en un estudio de fase avanzada. (Fuente: Latina TV)
- Redacción Trome
- 14 de oct. de 2021 04:46 p. m.
- Duración: 03:49
PLAYLIST
:quality(75)/cdn.jwplayer.com/v2/media/k3QH6hUo/poster.jpg)
Nuevo fármaco del laboratorio AstraZeneca ayuda a reducir riesgo de enfermedad grave
:quality(75)/cdn.jwplayer.com/v2/media/LOKCLaTj/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/mrnnazAT/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9CEIWu4A/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/iBmv0X5W/poster.jpg)
Lo último en Dr Trome
:quality(75)/cdn.jwplayer.com/v2/media/uLFcFqb5/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/47ZIYR5I3NHYLDYMX6HNEXHQWM.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/IgRLZjzm/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/jzNsG03q/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GPKZB3R6MFGSZPTKIVB3TELIJI.png)
:quality(75)/cdn.jwplayer.com/v2/media/yUicB3lY/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/y6dJDaLX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Eay6KXyw/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/B6wbn2mx/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/blYS7Abv/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/xhojB3zG/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c7KdMuSP/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/SB55C3XJR5DN3GFM2E2K66TKTE.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OQWZMLMB4NAMBMUEMUS23VBQF4.png)
:quality(75)/cdn.jwplayer.com/v2/media/soNYqLjW/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/2rMSAmQe/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/3x7E5IuB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/V1MLmIdz/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/tgOBgJkb/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/OCtzHKof/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LOKCLaTj/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/mrnnazAT/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9CEIWu4A/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/iBmv0X5W/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/IjOcBKT1/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/21MK8HYh/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/7C6UO42YLRG2NEBU3BSFA5CASI.png)
:quality(75)/cdn.jwplayer.com/v2/media/ZWmCs61m/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/3RRHC9KX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nA2o6uQg/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/N6HoVsFq/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/qyjpXBXq/poster.jpg)